Interpace Biosciences Inc
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $24.6M | $6.7M | $2.0M | $-22.0M | $-14.9M | $-26.5M | $-26.7M | $-12.7M |
| Depreciation & Amortization | $425.0K | $300.0K | $1.0M | $2.6M | $5.4M | $5.5M | $4.5M | $3.8M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | $900.0K | $1.3M | $3.2M | $4.5M | $4.0M | $3.6M |
| Stock-Based Compensation | $35.0K | $291.0K | $630.0K | $1.3M | $1.3M | $2.2M | $1.5M | $2.3M |
| Net Cash from Operating Activities | $5.8M | $4.6M | $3.8M | $-7.7M | $-8.7M | $-14.0M | $-19.0M | $-8.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $356.0K | $876.0K | $470.0K | $322.0K | $354.0K | $1.6M | $131.0K | $449.0K |
| Business Acquisitions | — | — | — | — | — | — | $13.8M | — |
| Net Cash from Investing Activities | $-356.0K | $-876.0K | $-87.0K | $6.2M | $-315.0K | $-1.6M | $-13.9M | $-449.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-4.4M | $-5.8M | $-5.0M | $3.0M | $9.0M | $16.6M | $29.2M | $-9.0K |
| Net Change in Cash | $1.0M | $-2.0M | $-1.3M | $1.5M | $-58.0K | $1.1M | $-3.7M | $-9.1M |
| Free Cash Flow | $5.5M | $3.8M | $3.3M | $-8.0M | $-9.1M | $-15.6M | $-19.1M | $-9.1M |